Zhang, X. (2025) The Hidden Double Burden: Formation Mechanisms of Stigma and Nursing Strategies for Male Breast Cancer ...

Scientists have found that a deadly tomb fungus called Aspergillus flavus may hold the key to promising new treatments for leukemia.

Expanding eligibility criteria for lung cancer screening to include 20-year smoking history without requiring a certain number of pack-years yielded a relative 28% increase in the number ...

A Delray Beach great-grandfather beat lung cancer with the help of an early diagnosis and robotic devices. Also in this month’s Your Health column: the newest global innovations in medical de… ...

DULUTH — Since being diagnosed with Stage 4 lung cancer in November 2024, running has taken on a new meaning for 37-year-old Caitlin Quinn of Duluth. A mother of three children between 2 and 7 ...

Smart nanoparticles launch genetic attack on lung cancer and cystic fibrosis Date: June 12, 2025 Source: Oregon State University Summary: A scientific team has unlocked a new way to treat serious ...

Doctors at the University of Louisville’s Brown Cancer Center have found that a new cancer treatment is showing promising results.

Johnson & Johnson has projected its lung cancer drug Rybrevant could achieve $5 billion in peak revenue. At the recent ASCO annual meeting, J&J executive Joshua Bauml explained his company’s ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...

Study shows that the use of immunotherapy with chemotherapy before lung cancer surgery reduces the risk of cancer returning and improves long term survival Earlier in his career as an oncologist ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer ...

Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3 ...